未登录 分享 收藏
Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: Subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks (LIMMitless trial) Strober, Bruce; Bachelez, Herve; Crowley, Jeffrey; Elewski, Boni E.; Gooderham, Melinda; Menter, Alan; Strohal, Robert; Chen, Michael M.; Wu, Tianshuang; Zhan, Tianyu; Photowala, Huzefa; Armstrong, April 分享 收藏
分享 收藏
分享 收藏
分享 收藏
Switching Between Adalimumab Reference Product and BI 695501 in Patients with Chronic Plaque Psoriasis (VOLTAIRE-X): A Randomized Controlled Trial Menter, Alan; Cohen, Stanley; Kay, Jonathan; Strand, Vibeke; Gottlieb, Alice; Hanauer, Stephen; Eduru, Sravan Kumar; Buschke, Susanne; Lang, Benjamin; Liesenfeld, Karl-Heinz; Schaible, Jennifer; McCabe, Dorothy 分享 收藏
Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2 Fernandez, A. P.; Dauden, E.; Gerdes, S.; Lebwohl, M. G.; Menter, M. A.; Leonardi, C. L.; Gooderham, M.; Gebauer, K.; Tada, Y.; Lacour, J. P.; Bianchi, L.; Egeberg, A.; Pau-Charles, I.; Mendelsohn, A. M.; Rozzo, S. J.; Mehta, N. N. 分享 收藏
分享 收藏
分享 收藏
分享 收藏
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial Thaci, Diamant; Strober, Bruce; Gordon, Kenneth B.; Foley, Peter; Gooderham, Melinda; Morita, Akimichi; Papp, Kim A.; Puig, Lluis; Menter, M. Alan; Colombo, Matthew J.; Elbez, Yedid; Kisa, Renata M.; Ye, June; Napoli, Andrew A.; Wei, Lan; Banerjee, Subhashis; Merola, Joseph F.; Gottlieb, Alice B. 分享 收藏
分享 收藏
分享 收藏
Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis Reich, K.; Mrowietz, U.; Menter, A.; Griffiths, C. E. M.; Bagel, J.; Strober, B.; Gomez, N. Nunez; Shi, R.; Guerette, B.; Lebwohl, M. 分享 收藏
分享 收藏
The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up Lebwohl, M.; Deodhar, A.; Griffiths, C. E. M.; Menter, M. A.; Poddubnyy, D.; Bao, W.; Jehl, V.; Marfo, K.; Primatesta, P.; Shete, A.; Trivedi, V.; Mease, P. J. 分享 收藏
Joint AADeNPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures Elmets, Craig A.; Korman, Neil J.; Prater, Elizabeth Farley; Wong, Emily B.; Rupani, Reena N.; Kivelevitch, Dario; Armstrong, April W.; Connor, Cody; Cordoro, Kelly M.; Davis, Dawn M. R.; Elewski, Boni E.; Gelfand, Joel M.; Gordon, Kenneth B.; Gottlieb, Alice B.; Kaplan, Daniel H.; Kavanaugh, Arthur; Kiselica, Matthew; Kroshinsky, Daniela; Lebwohl, Mark; Leonardi, Craig L.; Lichten, Jason; Lim, Henry W.; Mehta, Nehal N.; Paller, Amy S.; Parra, Sylvia L.; Pathy, Arun L.; Siegel, Michael; Stoff, Benjamin; Strober, Bruce; Wu, Jashin J.; Hariharan, Vidhya; Menter, Alan 分享 收藏
Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2) Lebwohl, Mark G.; Leonardi, Craig L.; Mehta, Nehal N.; Gottlieb, Alice B.; Mendelsohn, Alan M.; Parno, Jeff; Rozzo, Stephen J.; Menter, M. Alan 分享 收藏
分享 收藏
Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study 生物仿制药BI 695501和阿达木单抗参考产品在中度至重度慢性斑块状银屑病患者中具有相似的疗效，安全性和免疫原性: VOLTAIRE-PSO III期随机研究的结果 Menter, Alan; Arenberger, Petr; Balser, Sigrid; Beissert, Stefan; Cauthen, Ashley; Czeloth, Niklas; Soung, Jennifer; Jazayeri, Sasha; Weisenseel, Peter; Jayadeva, Girish 分享 收藏
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png)
OAAI
.png){kind=icon}
分享.png){kind=icon}
收藏